Aurora Completes Acquisition of Panvera | GenomeWeb

NEW YORK, March 1 - Aurora Biosciences said Thursday it completed its acquisition of Panvera, a Madison, Wisc.-based manufacturer of recombinant protein drug targets and protein drug screening assays.

Under the terms of the agreement, which has been approved by Panvera shareholders, Aurora will issue up to 1.9 million shares of its common stock in the transaction.

On November 17, the day the deal was originally announced, Aurora’s stock was trading just above $45 a share. Since then, the price has steadily fallen to about $18 a share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.